Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0699790 (
colon cancer
)
28,837
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The enzyme
beta1,4-N-acetylgalactosaminyltransferase III
(
beta4GalNAc-T3
) exhibits in vitro activity of synthesizing N,N'-diacetyllactosediamine, GalNAcbeta1,4GlcNAc. Here, we investigate the expression of
beta4GalNAc-T3
in primary colon tumors and the effects of its overexpression on HCT116
colon cancer
cells. Real-time reverse transcription-PCR showed that the expression of
beta4GalNAc-T3
was up-regulated in 72.5% (n = 40) of primary colon tumors compared with their normal counterparts.
beta4GalNAc-T3
overexpression resulted in enhanced cell-extracellular matrix adhesion, migration, anchorage-independent cell growth, and invasion of
colon cancer
cells. Moreover,
beta4GalNAc-T3
overexpression increased tumor growth and metastasis and decreased survival of tumor-bearing nude mice.
beta4GalNAc-T3
overexpression showed increased tyrosine phosphorylation of focal adhesion kinase and paxillin Y118 as well as increased extracellular signal-regulated kinase phosphorylation. These results suggest that up-regulation of
beta4GalNAc-T3
may play a critical role in promoting tumor malignancy and that integrin and mitogen-activated protein kinase signaling pathways could be involved in the underlying mechanism.
...
PMID:Beta1,4-N-acetylgalactosaminyltransferase III enhances malignant phenotypes of colon cancer cells. 1757 16
